|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | G01N 33/574 | (2006.01) |
| G01N 33/574 | (2013.01) | ||
| G01N 33/57415 | (2013.01) | ||
| G01N 33/57446 | (2013.01) |
| (11) | Patento numeris | 3797296 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 19727597.7 |
| Europos patento paraiškos padavimo data | 2019-05-20 | |
| (97) | Europos patento paraiškos paskelbimo data | 2021-03-31 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2024-09-04 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2019/062972 |
| Data | 2019-05-20 |
| (87) | Numeris | WO 2019/224153 |
| Data | 2019-11-28 |
| (30) | Numeris | Data | Šalis |
| 201862674566 P | 2018-05-21 | US |
| (72) |
MURILLO, Adrian E. , US
NITTA, Hiro , US
MUNROE, Donald G. , US
LO, Amy A. , US
KUWATA, Takeshi , JP
KAITO, Akio , JP
OCHIAI, Atsushi , JP
|
| (73) |
GENENTECH, INC. ,
1 DNA Way, South San Francisco, CA 94080,
US
Ventana Medical Systems, Inc. , 1910 E. Innovation Park Drive, Tucson, Arizona 85755, US National Cancer Center , 5-1-1, Tsukiji Chuo-ku, Tokyo 104-0045, JP |
| (54) | HER2 HETEROGENEITY AS A BIOMARKER IN CANCER |
| HER2 HETEROGENEITY AS A BIOMARKER IN CANCER |